← Eichor
Study identifier: NCT06365892 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis

Condition: Adolescent Idiopathic Scoliosis (AIS)  ·  Sponsor: University of California, San Francisco

PhaseNA
Planned participants64
Who can joinAll sexes, 10 Years to 18 Years
Healthy volunteersNo

About this study

This study aims to investigate the effects of conditioning with open-label placebos on standard postoperative treatment for patients undergoing surgery for idiopathic scoliosis in a randomized controlled, 6-week trial with 64 AIS patients randomly assigned to one of two arms: Open-label Placebo (COLP) + treatment as usual TAU / TAU control. The study involves collecting data from your child's medical record. At each regular clinic visit, the patient clinical data will be collected by the research coordinator. Surveys will be collected including:• PROMIS for the age group 10 to 18 years.

This description comes directly from the study's public registry record.

Talk to the study team

Mohammad Diab, MD  ·  415-514-1519  ·  mohammad.diab@ucsf.edu

Tripta Rughwani  ·  tripta.rughwani@ucsf.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of California, San FranciscoSan Francisco, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06365892